| Original language | English |
|---|---|
| Number of pages | 0 |
| Journal | Journal of Hepatology |
| Volume | 0 |
| Issue number | 0 |
| Early online date | 30 Mar 2022 |
| DOIs | |
| Publication status | Published - 30 Mar 2022 |
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
- Christopher L. Bowlus*
- , Michael R. Galambos
- , Richard J. Aspinall
- , Gideon M. Hirschfield
- , David E.J. Jones
- , Yvonne Dörffel
- , Stuart C. Gordon
- , Stephen A. Harrison
- , Andreas E. Kremer
- , Marlyn J. Mayo
- , Paul J. Thuluvath
- , Cynthia Levy
- , Mark G. Swain
- , Guy W. Neff
- , David A. Sheridan
- , Carmen M. Stanca
- , Christoph P. Berg
- , Aparna Goel
- , Mitchell L. Shiffman
- , John M. Vierling
*Corresponding author for this work
- University of California at Davis
- Piedmont Atlanta Hospital
- Portsmouth Hospitals University NHS Trust
- University Health Network University of Toronto
- Newcastle University
- Charité Universitätsmedizin Berlin
- Henry Ford Health System
- Pinnacle Clinical Research
- University of Oxford
- Friedrich-Alexander University Erlangen-Nürnberg
- University of Zurich
- University of Texas Southwestern Medical Center
- Mercy Medical Center Baltimore
- University of Maryland, Baltimore
- University of Miami
- University of Calgary
- LLC
- University Hospitals Plymouth NHS Trust
- New York University
- University of Tübingen
- Stanford University
- Liver Institute of Virginia
- Baylor College of Medicine
- Inc.
Research output: Contribution to journal › Article › peer-review
19
Downloads
(Pure)